Draft guidance has recommended afatinib (Giotrif) as a treatment for locally advanced, or metastatic, non-small-cell lung cancer.
The National Institute for Health and Care Excellence proposed that it be given to patients whose tumours test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and have not previously received an EGFR-TK inhibitor.
The drug, which is made by Boehringer Ingelheim, works by blocking the signal pathways helping to slow the growth and spread of tumours.
Sir Andrew Dillon, chief executive of NICE, said: “We’ve already recommended two drugs, gefitinib and erlotinib, as options for the first-line treatment for patients with this form of lung cancer and we’re pleased that this draft guidance recommends a further option.”
- Read the draft guidance from NICE